2026 John Tandy Myeloma Haematology Fellowship Announcement

Snowdome Foundation is proud to announce that Dr Kenneth Lim has been awarded the 2026 John Tandy Myeloma Haematology Fellowship.

Named in honour of Dr John Tandy, whose myeloma diagnosis was one of the inspirations behind the establishment of Snowdome Foundation, the fellowship reflects Snowdome Foundation’s commitment to driving progress in blood cancer treatments. By supporting exceptional researchers, the fellowship aims to accelerate the translation of scientific discovery into better treatments and ultimately better outcomes for patients living with multiple myeloma.

Dr Lim is a haematologist at The Alfred Hospital and Northern Health, and a PhD candidate in the Spencer Lab at the Australian Centre for Blood Diseases. As both a clinician and researcher, he works at the intersection of patient care and scientific innovation, placing him in a unique position to translate research discoveries into meaningful clinical impact.

His fellowship project focuses on some of the most promising advances in myeloma treatment today, including bispecific antibodies and CAR T-cell therapy. While these therapies have transformed treatment possibilities for many patients, significant questions remain around which patients are most likely to benefit, who may experience relapses, and how these therapies should be sequenced to achieve the best possible outcomes.

“Multiple myeloma remains incurable, but a new generation of T-cell redirecting therapies, namely bispecific antibodies and CAR T-cell therapy, are transforming what’s possible for patients,” said Dr Lim.

Through the fellowship, Dr Lim will investigate how patients’ immune systems respond to these therapies, with the goal of identifying which patients are most likely to benefit and how treatment can be tailored to achieve the best possible outcomes.

“By understanding how each patient’s immune system engages with, or fails to engage with, these therapies, we can begin to identify signatures that separate responders from non-responders,” said Dr Lim.

The ability to predict treatment responses more accurately could help clinicians make better-informed decisions and has the potential to help move the field closer to a future where treatment is tailored to the individual patient.

“The goal is precision: matching the right treatment to the right patient at the right time,” said Dr Lim. “This research has the potential to reduce unnecessary toxicity, guide treatment sequencing, and ultimately bring more myeloma patients closer to long-term disease control.”

The John Tandy Myeloma Haematology Fellowship reflects a commitment to investing in the people and ideas that will shape the future of myeloma treatment. By supporting outstanding researchers such as Dr Lim, Snowdome Foundation helps accelerate the journey from scientific discovery to patient benefit, ensuring that promising advances can reach the people who need them sooner.

Snowdome Foundation congratulates Dr Lim on this achievement and looks forward to following the impact of his research in the years ahead.